Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition - Yang, Lu; Zhang, Youyou; Shan, Weiwei; Hu, Zhongyi; Yuan, Jiao; Pi, Jingjiang; Wang, Yueying; Fan, Lingling; Tang, Zhaoqing; Li, Chunsheng; Hu, Xiaowen; Tanyi, Janos L; et al. (Science translational medicine, 2017)
Keywords: Acetanilides - therapeutic use; Animals; Antineoplastic Agents - therapeutic use; Azepines - therapeutic use; Benzodiazepines - therapeutic use; Breast Neoplasms - drug therapy; Cell Line, Tumor; DNA Damage - drug effects; DNA Damage - genetics; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring - therapeutic use; Homologous Recombination - drug effects; Homologous Recombination - genetics; Humans; Ovarian Neoplasms - drug therapy; Phthalazines - therapeutic use; Piperazines - therapeutic use; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Triazoles - therapeutic use